Androgen and androgen receptor antagonist responsive primary African-American benign prostate epithelial cell line

Anticancer Research

Volumn 25, Issue 1 A, 2005, Pages 1-8

  Gu, Yongpeng ^a   Kim, Kee Hong ^a   Ko, Daejin ^a   Srivastava, Shiv ^a   Moul, Judd W ^a   McLeod, David G ^b   Rhim, Johng S ^a,c  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c Center for Prostate Disease Research   (United States)

Author keywords

African American; Androgen; Androgen receptor antagonist; Benign human prostate cells; HTERT

Indexed keywords

AGAR; ANDROGEN; ANDROGEN RECEPTOR; ANDROGEN RECEPTOR ANTAGONIST; CELL ANTIGEN; CYTOKERATIN 8; HOMEODOMAIN PROTEIN; PROTEIN NKX3.1; PROTEIN P16; RECEPTOR BLOCKING AGENT; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG;

AFRICAN AMERICAN; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CELL IMMORTALIZATION; ENZYME ACTIVITY; EPITHELIUM CELL; GENE EXPRESSION; GENETIC TRANSDUCTION; HOMEOBOX; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SCID MOUSE; WESTERN BLOTTING;

AFRICAN CONTINENTAL ANCESTRY GROUP; ANDROGEN ANTAGONISTS; CELL GROWTH PROCESSES; CELL LINE; DNA-BINDING PROTEINS; EPITHELIAL CELLS; FLUTAMIDE; HUMANS; KARYOTYPING; MALE; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TELOMERASE; TRANSFECTION;

EID: 16344396583     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ and Thun MJ: Cancer statistics. CA Cancer J Clin 54: 8-29, 2004.
2. Moul JW: Targeted screening for prostate cancer in African-American men. Prostate Cancer Prostatic Dis 3: 248-255, 2000.
3. Veldscholte J, Berrevoets CA, Ris-Stalpers C, Kuiper GG, Jenster G, Trapman J, Brinkmann AO and Mulder E: The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. Steroid Biochem Mol Biol 41: 665-669, 1992.
4. Greider CW: Telomerase activation. One step on the road to cancer? Trends Genet 15: 109-112, 1999.
5. Sommerfeld HJ, Meeker AK, Piatyszek MA, Bova GS, Shay W and Coffey DS: Telomerase activity a prevalent marker of malignant human prostate tissue. Cancer Res 56: 218-222, 1996.
6. Morales CP, Holt SE, Ouellette M, Kaur KJ, Van Y, Wilson KS, White M A, Wright WE and Shay JW: Absence of cancer-associated changes in human fibroblasts immortalized with telomerase. Nat Genet 21: 115-118, 1999.
7. Jiang XR, Jimenez G, Chang E, Frolkis M, Kusler B, Sage M, Beeche M, Bodnar AG, Wahl GM, Tlsty TD and Chiu CP: Telomerase expression in human somatic cells does not induce changes associated with a transformed phenotype. Nat Genet 21: 111-114, 1999.
8. Ratsch SB, Gao Q, Srinivasan S, Wazer DE and Band V: Multiple genetic changes are required for efficient immortalization of different subtypes of normal human mammary epithelial cells. Radiat Res 155: 143-150, 2001.
9. Yasunaga Y, Nakamura K, Ewing CM, Isaacs WB, Hukku B and Rhim JS: A novel human cell culture model for the study of familial prostate cancer. Cancer Res 61: 5969-5973, 2001.
10. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL and Shay JW: Specific association of human telomerase activity with immortal cells and cancer. Science 266: 2011-2015, 1994.
11. Cline J, Braman JC and Hogrefe HH: PCR fidelity of pfu DNA polymerase and other thermostable DNA polymerases. Nucleic Acids Res 24: 3546-3551, 1996.
12. Hukku B and Rhim JS: Role of chromosome 5 in immortalization and tumorigenesis of human keratinocytes. Cancer Genet Cytogenet 68: 22-31, 1993.
13. Gaddipati JP, McLeod DG, Heidenberg HB, Sesterhenn IA, Finger MJ, Moul JW and Srivastava S: Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res 54: 2861-2864, 1994.
14. Lee C, Sutkowski DM, Sensibar JA, Zelner D, Kim I, Amsel I, Shaw N, Prins GS and Kozlowski JM: Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic cancer cells, LNCaP, by dihydrotestosterone. Endocrinology 136: 796-803, 1995.
15. de Launoit Y, Veilleux R, Dufour M, Simard J and Labrie F: Characteristics of the biphasic action of androgens and of the potent antiproliferative effects of the new pure antiestrogen EM-139 on cell cycle kinetic parameters in LNCaP human prostatic cancer cells. Cancer Res 51: 5165-5170, 1991.
16. Olea N, Sakabe K, Soto AM and Sonnenschein C: The proliferative effect of "anti-androgens" on the androgen-sensitive human prostate tumor cell line LNCaP. Endocrinology 126: 1457-1463, 1990.
17. Hukku B, Mally M, Cher ML, Peehl DM, Kung H and Rhim JS: Stepwise genetic changes associated with progression of nontumorigenic HPV-18 immortalized human prostate cancer-derived cell line to a malignant phenotype. Cancer Genet Cytogenet 120(2): 117-126, 2000.
18. Berthon P, Valeri A, Cohen-Akenine A, Drelon E, Paiss T, Wohr G, Latil A, Millasseau P, Mellah I, Cohen N, Blanche H, Bellane-Chantelot C, Demenais F, Teillac P, Le Duc A, de Petriconi R, Hautmann R, Chuma-kov I, Bachner L, Maitland NJ, Lidereau R, Vogel W, Fournier G, Mangin P and Cussenot O: Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43. Am J Hum Genet 62: 1416-1424,1998.
19. Gibbs M, Chakrabarti L, Stanford JL, Goode EL, Kolb S, Schuster EF, Buckley VA, Shook M, Hood L, Jarvik GP and Ostrander EA: Analysis of chromosome 1q42.2-43 in 152 families with high risk of prostate cancer. Am J Hum Genet 64: 1087-1095, 1999.
20. Cancel-Tassin G, Latil A, Valeri A, Mangin P, Fournier G, Berthon P and Cussenot O: PCAP is the major known prostate cancer predisposing locus in families from south and west Europe. Eur J Hum Genet 9: 135-142, 2001.
21. Smith JR, Freije D, Carpten JD, Gronberg H, Xu J, Isaacs SD, Brownstein MJ, Bova GS, Guo H, Bujnovszky P, Nusskern DR, Damber JE, Bergh A, Emanuelsson M, Kallioniemi OP, Walker-Daniels J, Bailey-Wilson JE, Beaty TH, Meyers DA, Walsh PC, Collins FS, Trent JM and Isaacs WB: Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science (Wash. DC) 274: 1371-1374, 1996.
22. Berry R, Schroeder JJ, French AJ, McDonnell SK, Peterson BJ, Cunningham JM, Thibodeau SN and Schaid DJ: Evidence for a prostate cancer-susceptibility locus on chromosome 20. Am J Hum Genet 67: 82-91, 2000.
23. Ittmann MM: Chromosome 10 alterations in prostate adenocarcinoma. Oncol Rep 5: 1329-1335, 1998.
24. Quan J, Jenkins RB and Bostwick DG: Genetic and chromosomal alterations in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. Eur Urol 35: 479-483, 1999.
25. Rhim JS, Webber MM, Bello D, Lee MS, Arnstein P, Chen LS and Jay G: Stepwise immortalization and transformation of adult human prostate epithelial cells by a combination of HPV-18 and v-Ki-ras. Proc Natl Acad Sci USA 97: 11874-11878, 1994.
26. Kaighn ME, Reddel RR, Lechner JF, Peehl DM, Camalier RF, Brash DE, Saffiotti U and Harris CC: Transformation of human neonatal prostate epithelial cells by strontium phosphate transfection with a plasmid containing SV40 early region genes. Cancer Res 49: 3050-3056, 1989.
27. Weijerman PC, Konig JJ, Wong ST, Niesters HG and Peehl DM: Lipofection-mediated immortalization of human prostatic epithelial cells of normal and malignant origin using human papillomavirus type 18 DNA. Cancer Res 54: 5579-5583, 1994.
28. Choo CK, Ling MT, Chan KW, Tsao SW, Zheng Z, Zhang D, Chan LC and Wong YC: Immortalization of human prostate epithelial cells by HPV 16 E6/E7 open reading frames. Prostate 40: 150-158, 1999.
29. Koochekpour S, Maresh GA, Katner A, Parker-Johnson Lee, Tae-jin, Hebert FE, Kao YS, Skinner J and Rayford W: Establishment and characterization of a primary androgen-responsive African American prostate cancer cell line, E006AA. Prostate 60: 141-152, 2004.